11 patents
Utility
Use of Ppar-delta Agonists In the Treatment of Disease
18 Jan 24
Described herein is the use sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.
Niall O'DONNELL, Lynn PURKINS, Alejandro DORENBAUM
Filed: 19 Sep 23
Utility
Crystalline Ppar-delta Agonist
4 Jan 24
Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARS agonist compound.
Susana DEL RIO GANCEDO, Osama SULEIMAN, Emma SHARP, Cristina BALOGH, Rachael LEE, Julie MACRAE, Neil FEEDER
Filed: 12 Jun 23
Utility
Methods of Making a Ppar-delta Agonist
28 Dec 23
Described herein are methods of making the PPARδ agonist compound (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetic acid, including salt forms thereof.
Michael Trevelyan WILLIAMS
Filed: 19 Nov 21
Utility
Crystalline PPARĪ“ agonist
1 Aug 23
Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.
Susana Del Rio Gancedo, Osama Suleiman, Emma Sharp, Cristina Balogh, Rachael Lee, Julie Macrae, Neil Feeder
Filed: 10 Jan 22
Utility
Use of Ppar-delta Agonists In the Treatment of Disease
27 Jul 23
Described herein is the use sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.
Niall O'DONNELL, Lynn PURKINS, Alejandro DORENBAUM
Filed: 25 Jan 23
Utility
Using of a Ppar-delta Agonist In the Treatment of Kidney Disease
24 Nov 22
Described herein is the use of a PPAR-delta agonist in the treatment of kidney diseases, wherein: the kidney disease is Alport syndrome, Goodpasture syndrome, thin basement membrane nephropathy (TBMN), focal segmental glomerulosclerosis (FSGS), benign familial hematuria (BFH), post-transplant anti-GBM (Glomerular Basement Membrane) nephritis, X-linked Alport syndrome (XLAS), autosomal recessive Alport syndrome (ARAS) or autosomal dominant Alport syndrome (ADAS).
Colin O'CARROLL, Niall O'DONNELL, Jeffrey MINER
Filed: 18 Sep 20
Utility
Crystalline Ppar-delta Agonist
5 May 22
Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.
Susana DEL RIO GANCEDO, Osama SULEIMAN, Emma SHARP, Cristina BALOGH, Rachael LEE, Julie MACRAE, Neil FEEDER
Filed: 10 Jan 22
Utility
Use of Ppar-delta Agonists In the Treatment of Mitochondrial Myopathy
21 Apr 22
Described herein is the use of PPARδ agonists in the treatment of mitochondrial myopathy.
Colin O'CARROLL, Niall O'DONNELL, Lynn PURKINS, Alex DORENBAUM
Filed: 20 Feb 20
Utility
Crystalline PPAR-delta agonist
8 Mar 22
Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.
Susana Del Rio Gancedo, Osama Suleiman, Emma Sharp, Cristina Balogh, Rachael Lee, Julie Macrae, Neil Feeder
Filed: 20 Jul 21
Utility
Use of a Ppar-delta Agonist In the Treatment of Fatty Acid Oxidation Disorders (Faod)
27 Jan 22
Described herein is the use of PPARδ agonists in the treatment of fatty acid oxidation disorders.
Colin O'CARROLL, Niall O'DONNELL, Lynn PURKINS, Alex DORENBAUM
Filed: 3 Feb 20
Utility
Crystalline Ppar-delta Agonist
27 Jan 22
Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.
Susana DEL RIO GANCEDO, Osama SULEIMAN, Emma SHARP, Cristina BALOGH, Rachael LEE, Julie MACRAE, Neil FEEDER
Filed: 20 Jul 21
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first